Belinostat

• Description:

  Belinostat (PXD101; PX105684) is a potent HDAC inhibitor with an IC50 of 27 nM in HeLa cell extracts.

• Product Name Alternative:

  PXD101; PX105684

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Autophagy; HDAC

• Type:

  Reference compound

• Related Pathways:

  Autophagy; Cell Cycle/DNA Damage; Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Belinostat.html

• Purity:

  99.97

• Solubility:

  DMSO : 100 mg/mL (ultrasonic) |Ethanol : 25 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=S(NC1=CC=CC=C1)(C2=CC(/C=C/C(NO)=O)=CC=C2)=O

• Molecular Formula:

  C15H14N2O4S

• Molecular Weight:

  318.35

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Plumb JA, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histonedeacetylase inhibitor PXD101. Mol Cancer Ther. 2003 Aug;2 (8) :721-8.|[2]Qian X, et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther. 2006 Aug;5 (8) :2086-95.|[3]Chia S, et al. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun. 2017 Sep 5;8 (1) :435.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  HDAC; HDAC6

• CAS Number:

  [866323-14-0]